Codexis Inc (CDXS) USD0.0001

Sell:$2.49Buy:$2.50$0.24 (10.62%)

NASDAQ:1.22%
Prices delayed by at least 15 minutes
Sell:$2.49
Buy:$2.50
Change:$0.24 (10.62%)
Prices delayed by at least 15 minutes
Sell:$2.49
Buy:$2.50
Change:$0.24 (10.62%)
Prices delayed by at least 15 minutes

Company Information

About this company

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Key people

Stephen G. Dilly
Chairman of the Board, President, Chief Executive Officer
Georgia L. Erbez
Chief Financial Officer
Kevin Norrett
Chief Operating Officer
Alison Moore
Executive Vice President, Chief Technical Officer
David V. Smith
Lead Independent Director
Cynthia Collins
Independent Director
Raymond De Vre
Independent Director
Byron L. Dorgan
Independent Director
Esther Martinborough
Independent Director
Click to see more

Key facts

  • EPIC
    CDXS
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1920051067
  • Market cap
    $193.03m
  • Employees
    188
  • Shares in issue
    82.84m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.